We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+26.04%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$25M
(+19%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
8.63%
Top 10 Holdings %
Top 10 Hldgs %
52.92%
Holding
50
New
18
Increased
7
Reduced
9
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QuidelOrtho
QDEL
|
+$8.77M |
| 2 |
Insulet
PODD
|
+$8.67M |
| 3 |
Illumina
ILMN
|
+$7.24M |
| 4 |
Standard BioTools
LAB
|
+$6.75M |
| 5 |
BNR
Burning Rock Biotech
BNR
|
+$5.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$5.71M |
| 2 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$5.31M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$5.3M |
| 4 |
Centene
CNC
|
+$4.92M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$4.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.74% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16B
| $12.6M | 8.08% |
81,442
+33,843
| +71% | +$4.86M |
|
|
2
Insulet
PODD
$11.5B
| $9.73M | 6.26% |
+41,147
| New | +$8.67M |
|
|
3
QuidelOrtho
QDEL
$1.14B
| $8.63M | 5.54% |
+39,314
| New | +$8.77M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $8.56M | 5.5% |
155,232
-16,084
| -9% | -$1.02M |
|
5
Guardant Health
GH
$21.5B
| $7.7M | 4.95% |
68,863
-27,176
| -28% | -$2.49M |
|
6
Cytokinetics
CYTK
$10.5B
| $7.37M | 4.73% |
340,253
+134,167
| +65% | +$3.14M |
|
|
7
Standard BioTools
LAB
$340M
| $7.27M | 4.67% |
+978,158
| New | +$6.75M |
|
|
NSTG
8
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.21M | 4.63% |
161,253
-58,324
| -27% | -$2.27M |
|
|
ARNA
9
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.98M | 4.49% |
93,308
-79,588
| -46% | -$5.31M |
|
|
10
Illumina
ILMN
$31B
| $6.32M | 4.06% |
+21,024
| New | +$7.24M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $6.26M | 4.03% |
102,462
-94,787
| -48% | -$4.8M |
|
12
Kura Oncology
KURA
$800M
| $6.14M | 3.95% |
+200,484
| New | +$4.43M |
|
13
UnitedHealth
UNH
$376B
| $5.82M | 3.74% |
18,666
+5,762
| +45% | +$1.77M |
|
|
BNR
14
Burning Rock Biotech
BNR
$93.9M
| $5.45M | 3.5% |
+21,736
| New | +$5.15M |
|
15
10x Genomics
TXG
$6B
| $5.42M | 3.49% |
43,512
-7,307
| -14% | -$767K |
|
16
Fate Therapeutics
FATE
$286M
| $4.53M | 2.91% |
113,366
+4,201
| +4% | +$147K |
|
|
HZNP
17
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.04M | 2.6% |
+51,995
| New | +$3.58M |
|
18
Forte Biosciences
FBRX
$1.57B
| $3.87M | 2.49% |
+3,193
| New | +$2.12M |
|
|
BMY.RT
19
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $3.51M | 2.26% |
1,560,327
-1,997,719
| -56% | -$5.71M |
|
|
ATRS
20
DELISTED
Antares Pharma, Inc.
ATRS
| $3.23M | 2.07% |
1,194,530
-104,672
| -8% | -$290K |
|
|
TPTX
21
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $3.19M | 2.05% |
36,571
+13,963
| +62% | +$973K |
|
|
NCNA
22
NuCana
NCNA
$5.49M
| $2.66M | 1.71% |
103
+69
| +203% | +$1.87M |
|
|
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.63M | 1.69% |
520,830
-12,802
| -2% | -$93.1K |
|
24
Pacific Biosciences
PACB
$435M
| $2.54M | 1.63% |
+257,044
| New | +$1.48M |
|
|
LITS
25
Lite Strategy Inc
LITS
$32.8M
| $2.46M | 1.58% |
+39,368
| New | +$2.37M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Asymmetry Capital Management held 50 positions worth $156M, up 19% from $131M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Asymmetry Capital Management deployed $13.4M of net new capital in Q3 2020, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was QuidelOrtho: 39,314 shares worth $8.63M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 86% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb Company Contingent Value Rights, an estimated $5.71M trimmed.
- Asymmetry Capital Management's largest Q3 2020 buy was QuidelOrtho: 39,314 shares worth $8.63M.
- Asymmetry Capital Management added most to Ascendis Pharma A/S in Q3 2020, an estimated $4.86M increase.
- Asymmetry Capital Management's biggest Q3 2020 reduction was Bristol-Myers Squibb Company Contingent Value Rights, cutting an estimated $5.71M.
- Asymmetry Capital Management fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $5.3M.
- Asymmetry Capital Management's ten largest holdings make up 53% of its $156M portfolio in Q3 2020.
- Asymmetry Capital Management opened 18 new positions and closed 16 in Q3 2020.
- Asymmetry Capital Management's portfolio value rose 19% quarter-over-quarter to $156M.
Based on Asymmetry Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.